[go: up one dir, main page]

GB201911063D0 - Formulations - Google Patents

Formulations

Info

Publication number
GB201911063D0
GB201911063D0 GBGB1911063.4A GB201911063A GB201911063D0 GB 201911063 D0 GB201911063 D0 GB 201911063D0 GB 201911063 A GB201911063 A GB 201911063A GB 201911063 D0 GB201911063 D0 GB 201911063D0
Authority
GB
United Kingdom
Prior art keywords
formulations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1911063.4A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tarian Biologics Ltd
Original Assignee
Tarian Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tarian Biologics Ltd filed Critical Tarian Biologics Ltd
Priority to GBGB1911063.4A priority Critical patent/GB201911063D0/en
Publication of GB201911063D0 publication Critical patent/GB201911063D0/en
Priority to PCT/GB2020/051844 priority patent/WO2021023977A1/en
Ceased legal-status Critical Current

Links

GBGB1911063.4A 2019-08-02 2019-08-02 Formulations Ceased GB201911063D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1911063.4A GB201911063D0 (en) 2019-08-02 2019-08-02 Formulations
PCT/GB2020/051844 WO2021023977A1 (en) 2019-08-02 2020-07-31 Formulations comprising corticotropin releasing hormone (crh) and alpha-2 macroglobulin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1911063.4A GB201911063D0 (en) 2019-08-02 2019-08-02 Formulations

Publications (1)

Publication Number Publication Date
GB201911063D0 true GB201911063D0 (en) 2019-09-18

Family

ID=67990866

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1911063.4A Ceased GB201911063D0 (en) 2019-08-02 2019-08-02 Formulations

Country Status (2)

Country Link
GB (1) GB201911063D0 (en)
WO (1) WO2021023977A1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
EP1469882B1 (en) 2002-01-28 2010-08-25 Aimsco Limited Treatment of nervous system diseases with goat serum
BRPI0513062A (en) 2004-07-08 2008-04-22 Aimsco Ltd pharmaceutical composition, method of stimulating pomc production in a patient, uses of an isolated crf peptide and an isolated pomc peptide, and methods of treating a disease, producing crf and curative, enhancer or prophylactic treatment of a disease
AU2013282995B2 (en) 2012-06-25 2018-10-04 Aimsco Limited Formulation comprising CRH and alpha - 2 - immunoglobulin
GB201322948D0 (en) * 2013-12-23 2014-02-12 Aimsco Ltd Improved formulation
GB201408171D0 (en) * 2014-05-08 2014-06-25 Aimsco Ltd Formulation and method of manufacture
GB201617175D0 (en) * 2016-10-10 2016-11-23 Iconic Intellectual Property Limited Assay

Also Published As

Publication number Publication date
WO2021023977A1 (en) 2021-02-11

Similar Documents

Publication Publication Date Title
GB201809976D0 (en) Novel formulations
IL287224A (en) Novel formulations comprising melflufen
GB201707189D0 (en) Novel formulations
GB201707188D0 (en) Novel formulations
IL290356A (en) Larazotide formulations
GB201915094D0 (en) New formulations
GB201904338D0 (en) Fluorouracil-containing formulations
IL284691A (en) Formulations
GB202117828D0 (en) New formulations
GB201707187D0 (en) Novel formulations
SG11202010097WA (en) Apixaban formulations
IL284688A (en) Formulation
GB201913232D0 (en) Aerosolisable formulation
GB202103785D0 (en) Formulations
GB201910092D0 (en) New formulations
GB202018889D0 (en) Formulations
GB202009684D0 (en) Formulations
GB202009685D0 (en) Formulations
GB201911063D0 (en) Formulations
GB201905105D0 (en) Formulations
GB201910093D0 (en) New formulations
SG11202011823SA (en) Activator-nucleator formulations
GB2587402B (en) Formulation
GB202115121D0 (en) Formulations
GB202115127D0 (en) Formulations

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)